Continue Both Medications with Close Monitoring
A creatinine increase of less than 30% after one week of SGLT2 inhibitor and spironolactone therapy in HFpEF is expected and acceptable—continue both medications with close monitoring of renal function and electrolytes. This modest rise represents hemodynamic adaptation rather than true kidney injury and should not prompt medication discontinuation 1.
Rationale for Continuation
The Canadian and European guidelines explicitly state that creatinine increases up to 30% are not unexpected when initiating RAAS-blocking agents (including spironolactone) and do not require stopping the drug 1. This principle extends to SGLT2 inhibitors, which can cause temporary eGFR reductions of up to 15% that typically resolve within 1-3 months 2.
Key Management Steps:
1. Verify the Creatinine Increase is Stable
- Recheck creatinine and potassium within 1 week
- If creatinine stabilizes at <30% increase from baseline, continue both medications
- Document baseline creatinine for comparison
2. Monitor Electrolytes and Renal Function
For spironolactone, ESC guidelines specify 3:
- Check at 1 and 4 weeks after initiation
- Then at 1,2,3, and 6 months after achieving maintenance dose
- Every 6 months thereafter
For SGLT2 inhibitors 4:
- Monitor within 3 months of initiation for eGFR stabilization
- More frequent monitoring when combined with spironolactone
3. Specific Thresholds for Dose Adjustment
Spironolactone 3:
- Halve the dose if creatinine rises to >220 μmol/L (2.5 mg/dL) or potassium >5.5 mmol/L
- Stop immediately if creatinine >310 μmol/L (3.5 mg/dL) or potassium ≥6.0 mmol/L
SGLT2 inhibitor 4:
- Consider specialist referral if creatinine increases >30% within 3 months
- Can continue if eGFR remains ≥25 mL/min/1.73 m² (dapagliflozin) or ≥20 mL/min/1.73 m² (empagliflozin) 2
Evidence Supporting Combination Therapy
The recent SOGALDI-PEF trial (2025) demonstrated that dapagliflozin plus spironolactone reduced NT-proBNP by 11% more than dapagliflozin alone in HFpEF patients 5. While this combination increased eGFR decline (-6.4 mL/min/1.73 m²) and potassium (+0.32 mmol/L), these changes were manageable with monitoring, and only 4.8% developed potassium >5.5 mmol/L 5.
Both drug classes have Class I recommendations for HFpEF in the 2025 Canadian guidelines 6, with SGLT2 inhibitors reducing heart failure hospitalization and cardiovascular death across the ejection fraction spectrum 6, 7, 8.
Common Pitfalls to Avoid
Do not prematurely discontinue medications for modest creatinine elevations <30%. This represents appropriate hemodynamic modulation, not nephrotoxicity 1.
Do not ignore volume status. Assess for volume depletion, which can exacerbate renal function changes when SGLT2 inhibitors, spironolactone, and loop diuretics are combined 2, 9.
Do not forget "sick day" management. Educate patients to temporarily hold SGLT2 inhibitors during acute dehydrating illnesses 2. Spironolactone should also be held during acute illness with worsening renal function 1.
Do not combine with triple RAAS blockade (ACEi + ARB + spironolactone) unless in a specialized heart failure clinic with close monitoring 1.
When to Refer
Consider specialist referral if 4:
- Progressive loss of kidney function beyond initial adaptation
- Persistent hyperkalemia despite dose adjustment
- Creatinine increase >30% that doesn't stabilize
- eGFR <30 mL/min/1.73 m²
- Inability to continue kidney-protective therapies due to adverse effects